

Validation data for Anti-hRANKL-hIgG1

<https://www.invivogen.com/anti-human-rankl-igg1-denosumab>

For research use only.

Version 23L06-AK

Anti-hRANKL-hIgG1 is a neutralizing monoclonal antibody (mAb) against the human receptor activator of nuclear factor- κ B ligand (hRANKL). Anti-hRANKL-hIgG1 features a human IgG1 constant region (Fc) and the variable region of denosumab which targets the transmembrane and soluble forms of the human RANKL antigen. The binding capacity of Anti-hRANKL-hIgG1 to the hRANKL antigen has been validated by ELISA, using coated hRANKL protein and a Anti-hIgG-HRP secondary antibody (Figure 1).

Validation of Anti-hRANKL-hIgG1 mAb by ELISA




Figure 1. Binding of Anti-hRANKL-hIgG1 mAb to coated human RANKL protein. Human RANKL (1 μ g/ml) was coated on ELISA plates overnight. A 3-fold serial dilution of the Anti-hRANKL-hIgG1 mAb (red curve) or the Anti- β -Gal-hIgG1 control antibody (grey curve) was performed for the capture step. An HRP-labelled anti-hIgG antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com